[Multicenter open study with docetaxel. Treatment of patients with locally advanced or metastatic breast carcinoma].
The efficacy and safety of docetaxel were evaluated in an open, multicentric, non comparative study involving 24 patients with locally advanced or metastatic breast cancer, eligible for second line or subsequent anticancer chemotherapy; the results confirm a global response around 50%, suggesting some advantages when compared to the usual treatments in this set of patients; the median duration of response, the median time to progression and the median time of survival were respectively, 309, 219 and 345 days; the main iatrogenic event was haematological, mainly in the white and red blood cells.
Campos
O
O
Maternidade Bissaya Barreto, Coimbra.
Gonçalves
I
I
Furtado
I
I
Espírito Santo
J
J
Alcazar
A
A
Pinguinha
A
A
Fráguas
A
A
Chumbo
M
M
Cunha
M J
MJ
Gouveia-Oliveira
A
A
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel
Estudo aberto multicêntrico com docetaxel. Tratamento de doentes com carcinoma da mama localmente avançado ou metastático.